No signs of progressive beta cell damage during 20 years of prospective follow-up of autoantibody-negative diabetes

Acta Diabetologica

Volumn 49, Issue 1, 2012, Pages 57-62

  Ekholm, E ^a   Gottsater A ^a   Dahlin, L B ^a   Sundkvist, G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C peptide; Diabetes mellitus; Follow up; HbA1c; Long term effects

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY; TRIACYLGLYCEROL; AUTOANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CELL DAMAGE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; KIDNEY FAILURE; LIPID BLOOD LEVEL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; MORTALITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SWEDEN; AGED; BLOOD; CELL DEATH; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED; PANCREAS DISEASE; PATHOLOGY; TIME;

ADULT; AGED; AUTOANTIBODIES; CELL DEATH; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INSULIN-SECRETING CELLS; MIDDLE AGED; PANCREATIC DISEASES; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84861698991     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0273-1     Document Type: Article

References (26)

1. Chase HP, MacKenzie TA, Burdick J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M (2004) Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes 5:16-19 (Pubitemid 38489440)
2. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC (2004) Insulin secretion in type 1 diabetes. Diabetes 53:426-433 (Pubitemid 38174559)
3. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Jama 281:2005-2012 (Pubitemid 29254858)
4. Borg H, Gottsater A, Fernlund P, Sundkvist G (2002) A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51:1754-1762 (Pubitemid 34564287)
5. Jin P, Huang G, Lin J, Luo S, Zhou Z (2011) Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol
6. Savola K, Bonifacio E, Sabbah E, Kulmala P, Vahasalo P, Karjalainen J, Tuomilehto-Wolf E, Merilainen J, Akerblom HK, Knip M (1998) IA-2 antibodies-a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 41:424-429 (Pubitemid 28157413)
7. Hawa MI, Fava D, Medici F, Deng YJ, Notkins AL, De Mattia G, Leslie RD (2000) Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 23:228-233 (Pubitemid 30071029)
8. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M (2000) Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23:1326-1332
9. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157 (Pubitemid 29019367)
10. Huang G, Wang X, Li Z, Li H, Li X, Zhou Z (2010) Insulin auto-antibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese. Acta Diabetol
11. Gaede P, Vedel P, Parving HH, Pedersen O (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353:617-622 (Pubitemid 29087981)
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
13. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910 (Pubitemid 23154174)
14. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G (2001) High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032-3038 (Pubitemid 32673462)
15. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G (1994) Islet cell antibodies are associated with beta-cell failure also in obese adult onset diabetic patients. Acta Diabetol 31:226-231
16. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G (1990) Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 33:561-568 (Pubitemid 20293164)
17. Borg H, Fernlund P, Sundkvist G (1997) Measurement of anti-bodies against glutamic acid decarboxylase 65 (GADA): two new 125I assays compared with [35S] GAD 65-ligand binding assay. Clin Chem 43:779-785
18. Borg H, Fernlund P, Sundkvist G (1997) Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 43:2358-2363 (Pubitemid 28022973)
19. Gottsater A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark A, Sundkvist G (1992) Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation. A comparison between insulin and C-peptide to measure insulin secretion. Scand J Clin Lab Invest 52:631-639
20. Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V (1986) Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 32:1867-1872 (Pubitemid 17018062)
21. Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304-2314 (Pubitemid 37059501)
22. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC (2004) Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53:1509-1516 (Pubitemid 38697663)
23. Turner RC, McCarthy ST, Holman RR, Harris E (1976) Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1:1252-1254
24. Hribal ML, Perego L, Lovari S, Andreozzi F, Menghini R, Perego C, Finzi G, Usellini L, Placidi C, Capella C et al (2003) Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. Faseb J 17:1340-1342
25. Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D'Alfonso R, Patera I, Cappa M, Nistico L, Baroni M et al (2003) The Gly972 ≥ Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes 52:887-890 (Pubitemid 36323600)
26. Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M et al (2004) The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27:1394-1398 (Pubitemid 38679989)